Aktie A3C6XX MAINZ BIOMED N.V.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Mainz Biomed N.V.

Aktien

A3C6XX

NL0015000LC2

MYNZ

Verzögert Nasdaq
Andere Börsenplätze
 16:09:37 28.05.2024 		% 5 Tage % 1. Jan.
0,63 USD +10,20 % Intraday Chart für Mainz Biomed N.V. +8,43 % -45,69 %
07.05. Mainz Biomed N.V. stellt auf der Digestive Disease Week eine Analyse seiner eAArly Detect Studie vor CI
25.04. Mainz Biomed meldet positive Topline-Ergebnisse einer gepoolten Studie zur Evaluierung neuartiger Mrna-Biomarker und des firmeneigenen Ai-Algorithmus für die Integration in eine klinische FDA-PMA-Studie zur Darmkrebsdiagnostik der nächsten Generation CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Mainz Biomed N.V. Presents an Analysis from Its eAArly Detect Study At Digestive Disease Week
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Mainz Biomed N : Announcement of Annual General Meeting of - Form 6-K
Mainz Biomed Reports Full Year 2023 Financial Results
Mainz Biomed Reports Full Year 2023 Financial Results
Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C6XX Aktie
  4. Nachrichten Mainz Biomed N.V.
  5. Andere Sprachen